Aimovig and Gastrointestinal perforation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal perforation is found among people who take Aimovig, especially for people who are female, 40-49 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Aimovig and have Gastrointestinal perforation. It is created by eHealthMe based on reports of 38,155 people who have side effects when taking Aimovig from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

38,155 people reported to have side effects when taking Aimovig.
Among them, 7 people (0.02%) have Gastrointestinal perforation.

What is Aimovig?

Aimovig has active ingredients of erenumab-aooe. eHealthMe is studying from 38,218 Aimovig users for its effectiveness, alternative drugs and more.

What is Gastrointestinal perforation?

Gastrointestinal perforation (hole in the digestive tract) is found to be associated with 1,858 drugs and 1,320 conditions by eHealthMe.

Number of Aimovig and Gastrointestinal perforation reports submitted per year:

Could Aimovig cause Gastrointestinal perforation?

Time on Aimovig when people have Gastrointestinal perforation *:

Gender of people who have Gastrointestinal perforation when taking Aimovig *:

female: 75 %
male: 25 %

Age of people who have Gastrointestinal perforation when taking Aimovig *:

Common drugs people take besides Aimovig *:

Common side effects people have besides Gastrointestinal perforation *:

Intestinal Obstruction: 4 people, 57.14%
Constipation: 3 people, 42.86%
Stress And Anxiety: 1 person, 14.29%
Gastroparesis Postoperative (delayed emptying of food from the stomach after surgery): 1 person, 14.29%
Appendix Disorder: 1 person, 14.29%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 14.29%
Asthma: 1 person, 14.29%
Depression: 1 person, 14.29%
Disability: 1 person, 14.29%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 14.29%

Common conditions people have *:

Migraine (headache): 3 people, 42.86%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 14.29%
Embolism (obstruction of an artery, typically by a clot of blood or an air bubble): 1 person, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Aimovig and have Gastrointestinal perforation?

Check whether Gastrointestinal perforation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Gastrointestinal perforation and when was it recovered:

Gastrointestinal perforation in Aimovig

Expand to all the drugs that have ingredients of erenumab-aooe:

Gastrointestinal perforation and drugs with ingredients of erenumab-aooe

Alternative drugs to, pros and cons of Aimovig:

Aimovig (38,218 reports)

Common Aimovig side effects:

Migraine (headache): 3,203 reports
Drug ineffective: 3,055 reports
Constipation: 2,982 reports
Headache (pain in head): 1,940 reports
Fatigue (feeling of tiredness): 1,375 reports
Hair loss: 1,199 reports
Dizziness: 1,106 reports

Browse all side effects of Aimovig:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Gastrointestinal perforation treatments and more:

Gastrointestinal perforation (15,900 reports)

COVID vaccines that are related to Gastrointestinal perforation:

Common drugs associated with Gastrointestinal perforation:

How the study uses the data?

The study uses data from the FDA. It is based on erenumab-aooe (the active ingredients of Aimovig) and Aimovig (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.